Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company that uses biomarkers and augmented intelligence to help physicians identify the source of chronic low back pain, has appointed Daniel Keefe as Commercial Director for the Western United States. The appointment, announced April 28, 2026, reflects the company's strategy to expand its footprint in a key region as demand for its Nociscan platform grows.
Keefe brings more than 20 years of experience in medical device and healthcare technology sales, including leadership roles at Centinel Spine, Brainlab, Zimmer Biomet, and Intuitive Surgical. Most recently, he served as Regional Sales Manager at Centinel Spine, where he consistently exceeded performance targets and delivered significant year-over-year growth across Northern California. His expertise spans capital equipment, surgical technologies, and advanced clinical solutions in spine, orthopedics, and image-guided surgery.
"Dan brings a proven track record of driving commercial growth and expanding adoption of innovative surgical technologies," said Brent Ness, Chief Executive Officer of Aclarion. "His deep experience working with spine surgeons and hospital systems, combined with his ability to build and scale high-performing territories, will be instrumental as we continue to grow our presence in the Western U.S. and support broader clinical use of Nociscan."
Nociscan is a cloud-based platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine by objectively quantifying chemical biomarkers associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain and demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated. The company has established a growing presence across the Western U.S., with engagement spanning both academic institutions and high-volume private practice spine centers, supported by strong volume growth.
"I'm excited to join Aclarion at a time when Nociscan is gaining meaningful traction across the clinical community," said Daniel Keefe. "The ability to provide physicians with objective insight into the source of pain represents a significant advancement in how chronic low back pain is evaluated. I look forward to working with physicians and spine centers across the Western U.S. to expand access to Nociscan and support its continued integration into clinical practice."
An estimated 266 million people worldwide live with chronic low back pain, making it one of the most pervasive health challenges. The expansion of Aclarion's commercial team underscores increasing demand for Nociscan, supported by triple-digit growth in utilization. The company's focus on deepening adoption in strategic regions like the Western U.S. is expected to drive further clinical integration of its technology.
For more information on Nociscan, visit Aclarion's website. To find a Nociscan center, view the site map here.
